Item 2.02 Results of Operations and Financial Condition.
On January 4, 2017, Abbott Laboratories completed the acquisition of St. Jude Medical, Inc. Beginning with the first quarter of 2017, Abbotts cardiovascular and neuromodulation (ACN) business will include its historical Vascular Products segment and the businesses of St. Jude Medical, Inc.
On January 25, 2017, Abbott issued comparable historic revenue for the ACN business for each quarter of 2016 and the full year in the following three categories: Rhythm Management and Heart Failure, Cardiovascular and Structural Heart, and Neuromodulation.
In order to provide investors with additional detail on the ACN business, Abbott will now be reporting ACNs sales results in the following six categories:
Rhythm Management
: This product category will include traditional pacemakers and implantable cardioverter-defibrillators (ICDs) and bi-ventricular cardiac resynchronization therapy pacemakers and ICDs.
Electrophysiology
: This product category will include atrial fibrillation products.
Heart Failure
: This product category will include ventricular assist devices and the CardioMEMs HF system.
Vascular
: This product category will include a broad line of coronary, endovascular, and vessel closure devices, diagnostic coronary imaging technology, and percutaneous heart pumps.
Structural Heart
: This product category will include heart valve replacement and repair devices, patent foramen ovale closure devices, and left atrial appendage closure products.
Neuromodulation
: This product category will include spinal cord stimulation products, dorsal root ganglion stimulation products, and deep brain stimulation products.
Please see Exhibit 99.1 for comparable revenue in each product category for each quarter of 2016 and for the full year.
The information contained in this Current Report on Form 8-K and the Exhibit hereto shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, or the Exchange Act.